Iterion Therapeutics

Iterion is developing a novel downstream inhibitor of the Wnt/β-catenin pathway to treat cancers resistant to the current standard of care. Its lead asset has demonstrated safety and efficacy in a completed clinical trial for desmoid tumors and has now entered a Phase 1b trial in liver cancer (HCC). By overcoming toxicity and tolerability challenges that have historically hindered Wnt-targeting therapies, Iterion aims to bring a new class of targeted treatments to oncology.